JP7461350B2 - Ａｒｇ１及び／又はａｒｇ２の阻害剤 - Google Patents

Ａｒｇ１及び／又はａｒｇ２の阻害剤 Download PDF

Info

Publication number
JP7461350B2
JP7461350B2 JP2021526441A JP2021526441A JP7461350B2 JP 7461350 B2 JP7461350 B2 JP 7461350B2 JP 2021526441 A JP2021526441 A JP 2021526441A JP 2021526441 A JP2021526441 A JP 2021526441A JP 7461350 B2 JP7461350 B2 JP 7461350B2
Authority
JP
Japan
Prior art keywords
cancer
formula
alkyl
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507474A (ja
JP2022507474A5 (enExample
Inventor
ジョエル ビーティー
コリーヌ ニコール フォーリー
レベッカ ルイーズ グレンジ
テザン ギュネイ
スティーブン ドナルド ジェイコブ
ヤロスロウ カリシアク
マンモーハン レディ レレティ
エリック アレン リンジ－
デバシス マンダール
エリック トーマス ニューコム
ジェイ パトリック パワーズ
ブランドン リード ローゼン
ヨンリ スー
アィン スー トラン
Original Assignee
アーカス バイオサイエンシーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーカス バイオサイエンシーズ インコーポレイテッド filed Critical アーカス バイオサイエンシーズ インコーポレイテッド
Publication of JP2022507474A publication Critical patent/JP2022507474A/ja
Publication of JP2022507474A5 publication Critical patent/JP2022507474A5/ja
Application granted granted Critical
Publication of JP7461350B2 publication Critical patent/JP7461350B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021526441A 2018-11-16 2019-11-15 Ａｒｇ１及び／又はａｒｇ２の阻害剤 Active JP7461350B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768284P 2018-11-16 2018-11-16
US62/768,284 2018-11-16
PCT/US2019/061657 WO2020102646A2 (en) 2018-11-16 2019-11-15 Inhibitors of arg1 and/or arg2

Publications (3)

Publication Number Publication Date
JP2022507474A JP2022507474A (ja) 2022-01-18
JP2022507474A5 JP2022507474A5 (enExample) 2022-11-24
JP7461350B2 true JP7461350B2 (ja) 2024-04-03

Family

ID=70731928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526441A Active JP7461350B2 (ja) 2018-11-16 2019-11-15 Ａｒｇ１及び／又はａｒｇ２の阻害剤

Country Status (12)

Country Link
US (1) US12226425B2 (enExample)
EP (1) EP3880685B1 (enExample)
JP (1) JP7461350B2 (enExample)
KR (1) KR102718333B1 (enExample)
CN (1) CN113382998A (enExample)
AR (1) AR117102A1 (enExample)
AU (1) AU2019379808C1 (enExample)
CA (1) CA3120196A1 (enExample)
ES (1) ES3034676T3 (enExample)
TW (1) TWI828800B (enExample)
UY (1) UY38476A (enExample)
WO (1) WO2020102646A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3173831A1 (en) 2020-03-19 2021-09-23 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
CA3179320A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
EP4341262A1 (en) 2021-05-21 2024-03-27 Arcus Biosciences, Inc. Axl inhibitor compounds
TW202325279A (zh) 2021-10-29 2023-07-01 美商阿克思生物科學有限公司 HIF-2α抑制劑及其使用方法
CN119156228A (zh) 2022-05-02 2024-12-17 艾库斯生物科学有限公司 抗tigit抗体及其用途
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
TW202421150A (zh) 2022-09-14 2024-06-01 美商阿克思生物科學有限公司 艾魯美冷之分散體
EP4602041A1 (en) 2022-10-14 2025-08-20 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
CN120091809A (zh) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂
EP4705292A1 (en) 2023-05-05 2026-03-11 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4788432A1 (en) 2023-10-06 2026-08-12 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525364A (ja) 2010-04-22 2013-06-20 マーズ インコーポレイテッド アルギナーゼ阻害剤およびそれらの治療用途
JP2013542223A (ja) 2010-10-26 2013-11-21 マーズ インコーポレイテッド アルギナーゼ阻害剤としてのボロネート
US20180009830A1 (en) 2014-12-29 2018-01-11 Oncoarendi Therapeutics S.A. Arginase inhibitors and their therapeutic applications
JP2018520352A (ja) 2015-06-23 2018-07-26 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害するための組成物および方法
WO2019245890A1 (en) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
BR0210149A (pt) 2001-05-09 2004-06-29 Newbiotics Inc Pródrogas ativadas por deformilase de peptìdeo
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
SI2318419T2 (sl) 2008-06-17 2025-10-30 Takeda Pharmaceutical Company Limited Spojine boronat estra in njihovi farmacevtski sestavki
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
RU2488390C2 (ru) 2008-12-29 2013-07-27 Тартуский Университет Ингибиторы аргиназы для лечения депрессии
WO2010085797A2 (en) 2009-01-26 2010-07-29 The Trustees Of University Of Pennsylvania Arginase inhibitors and methods of use
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
PH12012500562A1 (en) * 2009-09-25 2012-10-22 Takeda Pharmaceuticals Co Novel npr-b antagonists
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
RU2019121905A (ru) 2010-12-31 2019-09-03 Астразенека Юкей Лимитед Ингибиторы аргиназы и способы их применения
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CA2852685C (en) 2011-10-19 2019-02-26 Mars, Incorporated Inhibitors of arginase and their therapeutic application
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CN104540836B (zh) * 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
WO2014007831A1 (en) 2012-07-06 2014-01-09 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EP3008051A4 (en) 2013-06-12 2017-03-01 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US9663491B2 (en) 2014-04-15 2017-05-30 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
CL2014002403A1 (es) 2014-09-11 2015-01-09 Univ Pontificia Catolica Chile Metodo para la preparacion enantioselectiva y purificacion del acido 2(s)-amino-6-boronohexanoico (abh) a partir de la disolucion de bpb-ni-gly en tetrahidrofurano, neutralizacion y posterior extraccion con diclorometano, disolucion en un alcohol c1-c5, enfriamiento para lograr la precipitacion de bpb, obtencion de abh y su posterior purificacion.
WO2016100555A1 (en) 2014-12-18 2016-06-23 Inception 4, Inc. Boronic acid derivatives and uses thereof
DK3368541T3 (da) 2015-10-30 2020-06-29 Calithera Biosciences Inc Sammensætninger og metoder til inhibiering af arginaseaktivitet
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3490542A4 (en) 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2019173188A1 (en) 2018-03-05 2019-09-12 Arcus Biosciences, Inc. Arginase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525364A (ja) 2010-04-22 2013-06-20 マーズ インコーポレイテッド アルギナーゼ阻害剤およびそれらの治療用途
JP2013542223A (ja) 2010-10-26 2013-11-21 マーズ インコーポレイテッド アルギナーゼ阻害剤としてのボロネート
US20180009830A1 (en) 2014-12-29 2018-01-11 Oncoarendi Therapeutics S.A. Arginase inhibitors and their therapeutic applications
JP2018520352A (ja) 2015-06-23 2018-07-26 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ活性を阻害するための組成物および方法
WO2019245890A1 (en) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use

Also Published As

Publication number Publication date
EP3880685A4 (en) 2022-07-27
AU2019379808B2 (en) 2023-08-03
JP2022507474A (ja) 2022-01-18
EP3880685B1 (en) 2025-06-18
KR20210108954A (ko) 2021-09-03
UY38476A (es) 2020-06-30
ES3034676T3 (en) 2025-08-21
EP3880685A2 (en) 2021-09-22
TW202033203A (zh) 2020-09-16
TWI828800B (zh) 2024-01-11
US20220016143A1 (en) 2022-01-20
US12226425B2 (en) 2025-02-18
AU2019379808A1 (en) 2021-06-24
WO2020102646A2 (en) 2020-05-22
AU2019379808C1 (en) 2024-01-25
KR102718333B1 (ko) 2024-10-17
CA3120196A1 (en) 2020-05-22
AR117102A1 (es) 2021-07-14
WO2020102646A3 (en) 2020-08-13
CN113382998A (zh) 2021-09-10
EP3880685C0 (en) 2025-06-18

Similar Documents

Publication Publication Date Title
KR102718333B1 (ko) Arg1 및/또는 arg2의 억제제
JP7394831B2 (ja) ピリドンａ２ｒアンタゴニスト
KR102656571B1 (ko) 아르기나아제 억제제
ES2953349T3 (es) Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer
CA3163338A1 (en) Inhibitors of hif-2alpha
CN110049767A (zh) 腺苷5′-核苷酸酶的抑制剂
HK40055656A (en) Inhibitors of arg1 and/or arg2
HK40039632A (en) Arginase inhibitors
EA043755B1 (ru) Ингибиторы аргиназы
HK40054296B (en) Pyridone a2r antagonists
HK40054296A (en) Pyridone a2r antagonists
HK40024629B (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
HK40024629A (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240322

R150 Certificate of patent or registration of utility model

Ref document number: 7461350

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150